TY - JOUR
T1 - Preclinical Studies on Convalescent Human Immune Plasma-Derived Exosome
T2 - Omics and Antiviral Properties to SARS-CoV-2
AU - Taşlı, Neslihan Pakize
AU - Gönen, Zeynep Burçin
AU - Kırbaş, Oğuz Kaan
AU - Gökdemir, Nur Seda
AU - Bozkurt, Batuhan Turhan
AU - Bayrakcı, Buse
AU - Sağraç, Derya
AU - Taşkan, Ezgi
AU - Demir, Sevda
AU - Ekimci Gürcan, Nur
AU - Bayındır Bilgiç, Melike
AU - Bayrak, Ömer Faruk
AU - Yetişkin, Hazel
AU - Kaplan, Büşra
AU - Pavel, Shaikh Terkıs Islam
AU - Dinç, Gökçen
AU - Serhatlı, Müge
AU - Çakırca, Gamze
AU - Eken, Ahmet
AU - Aslan, Vedat
AU - Yay, Mehmet
AU - Karakukcu, Musa
AU - Unal, Ekrem
AU - Gül, Fethi
AU - Basaran, Kemal Erdem
AU - Ozkul, Yusuf
AU - Şahin, Fikrettin
AU - Jones, Olcay Y.
AU - Tekin, Şaban
AU - Özdarendeli, Aykut
AU - Cetin, Mustafa
N1 - Publisher Copyright:
Copyright © 2022 Taşlı, Gönen, Kırbaş, Gökdemir, Bozkurt, Bayrakcı, Sağraç, Taşkan, Demir, Ekimci Gürcan, Bayındır Bilgiç, Bayrak, Yetişkin, Kaplan, Pavel, Dinç, Serhatlı, Çakırca, Eken, Aslan, Yay, Karakukcu, Unal, Gül, Basaran, Ozkul, Şahin, Jones, Tekin, Özdarendeli and Cetin.
PY - 2022/3/24
Y1 - 2022/3/24
N2 - The scale of the COVID-19 pandemic forced urgent measures for the development of new therapeutics. One of these strategies is the use of convalescent plasma (CP) as a conventional source for passive immunity. Recently, there has been interest in CP-derived exosomes. In this report, we present a structural, biochemical, and biological characterization of our proprietary product, convalescent human immune plasma-derived exosome (ChipEXO), following the guidelines set forth by the Turkish Ministry of Health and the Turkish Red Crescent, the Good Manufacturing Practice, the International Society for Extracellular Vesicles, and the Gene Ontology Consortium. The data support the safety and efficacy of this product against SARS-CoV-2 infections in preclinical models.
AB - The scale of the COVID-19 pandemic forced urgent measures for the development of new therapeutics. One of these strategies is the use of convalescent plasma (CP) as a conventional source for passive immunity. Recently, there has been interest in CP-derived exosomes. In this report, we present a structural, biochemical, and biological characterization of our proprietary product, convalescent human immune plasma-derived exosome (ChipEXO), following the guidelines set forth by the Turkish Ministry of Health and the Turkish Red Crescent, the Good Manufacturing Practice, the International Society for Extracellular Vesicles, and the Gene Ontology Consortium. The data support the safety and efficacy of this product against SARS-CoV-2 infections in preclinical models.
KW - convalescence plasma
KW - COVID-19
KW - exosome
KW - extracellular vehicles (EVs)
KW - SARS-CoV-2
KW - viral treatment
UR - http://www.scopus.com/inward/record.url?scp=85127881305&partnerID=8YFLogxK
U2 - 10.3389/fimmu.2022.824378
DO - 10.3389/fimmu.2022.824378
M3 - Article
C2 - 35401544
AN - SCOPUS:85127881305
SN - 1664-3224
VL - 13
JO - Frontiers in Immunology
JF - Frontiers in Immunology
M1 - 824378
ER -